Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Symptom control in advanced frailty
Medicine of older adults · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
Action: Stay with the person, summon experienced help, use the agreed emergency plan and route, and reassess response before repeating sedating or opioid medicines.
Purpose and principles
Relieve pain, breathlessness, nausea, delirium, anxiety and secretions with cause-led non-drug care, low starting doses and vigilant organ-function review.
Advanced frailty changes both symptom expression and medicine handling. Pain may appear as grimacing, guarding, calling out or reduced movement rather than a clear report. Breathlessness can arise from heart failure, COPD, infection, anaemia, anxiety or deconditioning. Agitation is commonly multifactorial. A calm bedside assessment should look for a treatable contributor while matching intervention burden to the person's goals and expected time to benefit.
Begin with reversible, low-burden measures: reposition for pressure pain or secretions; elevate the head and use cool airflow for breathlessness; empty a full bladder; treat constipation; reduce noise; provide familiar reassurance; moisten the mouth; and adjust dentures or oxygen tubing. Oxygen is not routinely helpful for breathlessness in a non-hypoxaemic person, although it may benefit known or suspected symptomatic hypoxaemia.
Prescribing should state medicine, indication, route, dose, minimum interval, maximum use and the review threshold. The examples below are conservative UK palliative starting regimens and must be reconciled with previous exposure, local formulary, compatibility guidance and individual renal or hepatic function. An opioid-tolerant person needs a calculated equivalent dose; do not
Indications, selection and cautions
Pain
Ask about site, quality and movement relation; when speech is limited, use a behavioural tool and look for guarding, grimacing, resistance or vocalisation.
Breathlessness
Assess subjective distress alongside respiratory pattern, posture, wheeze, crackles, oedema, infection and anxiety; oxygen saturation alone does not measure suffering.
Nausea and vomiting
Distinguish medicine or metabolic nausea, gastric stasis, constipation, raised intracranial pressure and complete obstruction because antiemetic choice and prokinetic safety differ.
Delirium and agitation
Look for fluctuation, inattention, fear, hallucinations and restlessness, then check pain, bladder, bowel, hypoxia, withdrawal, environment and medicine toxicity.
Respiratory secretions
Identify pooled upper-airway fluid in a person with a weak swallow and cough, while excluding pulmonary oedema or infection that needs different management.
Medicine toxicity
New sedation, slowed breathing, myoclonus, vivid dreams or hallucinations after declining renal function should trigger opioid review before further escalation.
Red flags requiring action
Bradypnoea, pinpoint pupils, new myoclonus, hallucinations or profound sedation suggest opioid toxicity, particularly after acute kidney injury.
Sudden agitation may represent urinary retention, faecal impaction, pain, hypoxia, hypoglycaemia, medicine withdrawal or an unsafe environment.
Assessment before treatment
01Focused symptom assessmentFirst step
Why
Measure distress and identify its mechanism.
Interpretation and limitations
Use the person's report where possible, behavioural tools when not, and a clear baseline against which each intervention can be judged.
02Bedside reversible-cause check
Why
Find immediately remediable sources of discomfort.
Interpretation and limitations
Examine mouth, position, bladder, bowel, skin, respiratory pattern and environment before attributing all distress to irreversible dying.
03Medicine and exposure reconciliation
Why
Prevent duplication, withdrawal and conversion error.
Interpretation and limitations
Calculate total opioid and sedative use over 24 hours, include patches and breakthrough doses, and verify time-critical anticonvulsant or Parkinson treatment.
04Renal and hepatic review
Why
Select a safe drug and interval.
Interpretation and limitations
Use recent results and trajectory where available; falling urine output or clinical liver failure may require avoidance, dose reduction or specialist opioid rotation.
05Targeted physiological test
Why
Answer a focused treatment-changing clinical question.
Treatment approach
01First lineCause-led comfort routeFirst stepFirst lineA new or worsening symptom is causing distress in advanced frailty.+
1EscalationDefine the symptom and goal, examine for reversible contributors and review the current escalation and capacity context.
2Apply proportionate non-drug measures immediately, including positioning, airflow, reassurance, mouth care, bladder or bowel relief.
3Choose one cause-matched medicine at a low appropriate dose, specify the route and review interval, and explain expected benefit.
4EscalationReassess benefit and adverse effects promptly before repeating, escalating or adding another sedating medicine.
02OpioidPain or breathlessness routeOpioid-responsive pain or persistent breathlessness remains despite suitable non-drug and cause-specific treatment.
Regimens, contraindications and interactions
Relieves opioid-responsive pain and can reduce distressing breathlessness after non-drug and cause-specific measures.
Morphine sulfate injection
If opioid-naive and without severe renal impairment, give 2 mg SC up to hourly as required; seek review after three doses in four hours or six doses in 24 hours.
Start lower in marked frailty; avoid or rotate with specialist advice in stage 4–5 kidney disease, and monitor sedation, respiratory rate, delirium and myoclonus.
Provides a low-dose therapeutic trial for persistent breathlessness when swallowing remains safe and reversible causes are addressed.
Immediate-release oral morphine
For opioid-naive breathlessness, trial 2 mg orally as required up to hourly, maximum six doses and 12 mg in 24 hours; in frailty consider 1 mg no more often than two-hourly.
Use the frailty regimen cautiously, prescribe bowel care when appropriate, and avoid routine initiation in severe renal impairment or established opioid toxicity.
Renal-appropriate potent opioid for pain or breathlessness when morphine metabolite accumulation makes usual regimens unsafe.
Alfentanil injection
Specialist initiation in very low eGFR: an opioid-naive example is 100 micrograms SC hourly as required or 500 micrograms by continuous SC infusion over 24 hours.
High potency and short action create error risk; obtain palliative advice, reduce by about 30–50% in hepatic impairment, check interactions and never confuse with fentanyl.
Complications, monitoring and follow-up
Record symptom severity and the person's desired balance between relief and alertness before treatment and after each early dose.
Count all as-required doses by indication and route over 24 hours; frequent use triggers cause review and possible infusion adjustment.
Monitor respiratory rate, arousability, hallucinations and myoclonus during opioid titration, especially when urine output falls.
Check bladder, bowel, mouth, pressure areas and infusion site during each nursing review because these commonly generate hidden distress.
Review compatibility, pump contents, remaining volume and breakthrough prescription whenever a continuous subcutaneous infusion changes.
Assess family understanding of expected breathing, secretions and medicine intent, correcting fears that appropriate opioids are being used to cause death.
Arrange same-day specialist advice for refractory symptoms, complex renal or hepatic impairment, uncertain conversions or disproportionate sedation.
Special situations
Subjective breathlessness matters
A person can be severely breathless with a normal oxygen saturation; judge treatment by distress and response, not the oximeter alone.
Opioids are not sedatives
The target is pain or breathlessness relief at the lowest effective dose. Unwanted somnolence should prompt reassessment, not celebration.
Patches usually continue
Continue an established fentanyl patch in the last days and calculate separate breakthrough treatment; do not initiate a patch for rapidly changing symptoms.
Pump is maintenance
A continuous infusion takes time to achieve control and cannot substitute for a prescribed, correctly calculated rescue dose during acute distress.
Parkinsonism changes antiemetics
Dopamine-blocking antiemetics can worsen rigidity and swallowing; obtain specialist or pharmacy advice for a neurologically safer choice.
Secretions need explanation
Repositioning and family reassurance are often as important as antimuscarinics, which reduce new fluid but cannot clear what is already present.
Renal decline changes yesterday's dose
A previously tolerated morphine regimen can become toxic after dehydration or acute kidney injury, so review exposure whenever physiology changes.
Common pitfalls
01
Escalating an opioid for every moan or movement without assessing retention, pressure pain, fear or delirium.
02
Starting oxygen solely because a person reports breathlessness despite no suspected symptomatic hypoxaemia.
03
Using morphine unchanged after severe renal deterioration and misreading emerging myoclonus as terminal agitation.
04
Prescribing a syringe pump without breakthrough doses, device checks, compatibility confirmation or a review plan.
05
Combining several sedatives rapidly before waiting for onset and observing the effect of the first dose.
06
Giving metoclopramide in complete bowel obstruction or dopamine antagonists to someone with Parkinson's disease.
07
Suctioning upper-airway secretions repeatedly when positioning, fluid review and explanation would cause less distress.
08
Leaving anticipatory medicines in the home without clear indications, trained administration and a 24-hour advice contact.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Medicine of older adultsOriginal SBA
Pain with severe renal failure
An opioid-naive patient in the last days has severe pain, eGFR 9 mL/min and new myoclonus after morphine. What is the safest approach?
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
reset them to an opioid-naive regimen. Conversion ratios are approximate, so round conservatively and monitor.
Severe renal dysfunction is especially important. Morphine, codeine and several active metabolites can accumulate, causing drowsiness, confusion, hallucination, myoclonus and respiratory depression. In very low eGFR or rapidly falling renal function, specialist-guided alfentanil is commonly preferred because active metabolites do not accumulate, although hepatic clearance and interactions still matter. Severe liver failure also requires lower doses and slower titration of opioids and sedatives.
Anticipatory medicines should be available before a crisis in the chosen care setting, but they are not administered merely because death is expected. Nurses and carers need a written indication and contact route. Review at least daily, sooner after dose changes, and seek specialist palliative input when symptoms do not improve promptly, toxicity emerges, several medicines must share a pump or the desired balance between alertness and relief is difficult to achieve.
Key points
Assess the symptom, likely cause, severity, reversible contributors and the person's goal before selecting a medicine.
Non-drug measures remain active treatment: repositioning, a fan, quiet reassurance, mouth care, bladder and bowel relief can work quickly.
Choose oral or buccal routes while swallowing is reliable; use subcutaneous rather than intramuscular administration when oral treatment fails.
In frailty, start below standard adult doses when appropriate, titrate to observed benefit and check after every early dose.
Morphine metabolites accumulate in severe renal impairment; seek palliative advice and use a renal-appropriate opioid regimen.
A continuous subcutaneous infusion maintains control but does not deliver rescue treatment; prescribe compatible breakthrough medicines separately.
More than two or three effective as-required doses in 24 hours may justify incorporating their total into a reviewed 24-hour infusion.
Sedation is a possible adverse effect, not the intended purpose of opioids; refractory distress requiring deeper sedation needs specialist oversight.
New stridor, massive haemoptysis, haematemesis or rapidly increasing breathlessness requires the pre-agreed emergency response and senior support.
Repeated as-required doses provide little benefit, indicating a wrong cause, wrong route, toxicity or need for specialist titration.
A syringe pump is started automatically without calculating previous opioid exposure, checking compatibility or prescribing breakthrough doses.
Haloperidol or metoclopramide is proposed in Parkinson's disease or Lewy body dementia without recognising extrapyramidal risk.
Interpretation and limitations
Glucose, oxygen saturation, bladder scan or limited blood testing is justified when it could reveal a rapidly treatable contributor consistent with goals.
06Subcutaneous compatibility check
Why
Prevent pump precipitation and dosing failure.
Interpretation and limitations
Confirm concentration, diluent, device, drug compatibility and local administration policy with pharmacy or specialist guidance before combining medicines.
+
1Establish opioid exposure, eGFR, hepatic function, swallowing and signs of toxicity before calculating a starting or breakthrough dose.
2For an opioid-naive person without severe renal impairment, trial the lowest local oral or subcutaneous morphine regimen and observe response.
3For an opioid-tolerant person, use a conservative conversion and prescribe breakthrough treatment generally based on one sixth to one tenth of the regular 24-hour dose.
4Seek specialist advice for severe renal disease, complex conversion, refractory pain or toxicity, and address constipation while oral intake continues.
03PersistentContinuous infusion reviewSymptoms recur despite effective intermittent doses or the oral route is no longer reliable.+
1Total the effective doses used in the preceding 24 hours and distinguish persistent symptoms from repeated ineffective treatment.
2Calculate a conservative 24-hour subcutaneous regimen, check device and drug compatibility and retain separate rescue prescriptions.
3Review the infusion site, delivery, alertness, symptom score and rescue use at least daily and after any titration.
4Request specialist input when more than three doses in four hours or more than six in 24 hours are needed, or benefit remains poor.
04RefractorySpecialist distress routeSevere symptoms continue despite correct assessment, route, drug choice and proportionate titration.+
1Reassess diagnosis, retention, impaction, toxicity, interaction, pump failure and psychological or spiritual distress with experienced clinicians.
2Clarify the person's priorities concerning alertness and symptom relief, involving the lawful decision process if capacity is absent.
3Use specialist-guided medicine combination or palliative sedation only for refractory distress, with a documented indication and proportional target.
4Support family and staff, explaining intended symptom relief, monitoring and the distinction from deliberately causing death.
Treats severe anxiety, panic or terminal agitation when non-drug measures and correction of reversible causes are insufficient.
Midazolam injection
For intermittent terminal anxiety or agitation, give 2 mg SC hourly as required; persistent distress may use 10–20 mg over 24 hours by SC infusion after review.
Use the lowest dose in frailty, monitor unintended sedation and respiratory depression, and seek urgent advice after three ineffective doses in four hours.
Can reduce nausea and selected delirium symptoms when the mechanism and patient's neurological condition make dopamine blockade appropriate.
Haloperidol injection
For metabolic or medicine-related nausea or delirium, a low starting regimen is 500 micrograms to 1 mg SC every eight hours as required, then review.
Avoid in Parkinson's disease and Lewy body dementia; consider QT prolongation, extrapyramidal effects, akathisia and lower dosing in frail or hepatic impairment.
Broad-spectrum antiemetic and specialist adjunct for refractory terminal delirium when simpler cause-specific options have not worked.
Levomepromazine injection
For complex nausea in the last days, give 2.5–5 mg SC every 12 hours as required; different terminal-agitation doses require specialist direction.
May cause profound sedation, hypotension, anticholinergic effects and QT prolongation; start at the lowest dose in frailty and do not confuse antiemetic with sedative dosing.
Reduces production of new upper-airway secretions after repositioning and review of fluid or feeding burden.
Hyoscine butylbromide injection
For distressing respiratory secretions, give 20 mg SC up to hourly as required, with a maximum total of 120 mg in 24 hours before review.
It does not remove existing secretions; monitor dry mouth, urinary retention and anticholinergic burden, and avoid repeated dosing without evidence of benefit.
Alternative peripheral antimuscarinic for noisy respiratory secretions in the last days of life.
Glycopyrronium bromide injection
If secretions persist or hyoscine butylbromide is unsuitable, give 200 micrograms SC every six to eight hours as required and reassess.
Can worsen dry mouth, thick secretions and urinary retention; explain that the sound may persist and avoid routine suction that increases distress.
Treats mild musculoskeletal pain or fever and can reduce the opioid dose required when the route remains practical.
Paracetamol
Give 500 mg to 1 g orally or rectally every four to six hours as required, maximum 4 g in 24 hours; use 500 mg doses in low weight or organ impairment.
Use a lower daily maximum in weight below 50 kg, malnutrition, hepatic disease or alcohol excess, and include combination products in the total.